Olaparib has been approved for patients with breast, ovarian, pancreatic, or prostate cancer who had HRD or BRCA1/2 mutations with PVs, whereas niraparib has been approved for patients with ovarian cancer who had HRD or BRCA1/2 mutations with PVs. This evidence concerns the gene BRCA1 and Familial prostate cancer.